Celcuity, Inc. (NASDAQ:CELC - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $53.30 and last traded at $53.3590, with a volume of 440,089 shares trading hands. The stock had previously closed at $56.31.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Celcuity in a research report on Thursday, October 22nd. They set an "overweight" rating and a $140.00 price objective on the stock. Needham & Company LLC reduced their price objective on shares of Celcuity from $140.00 to $134.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Stifel Nicolaus reduced their target price on Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Guggenheim assumed coverage on Celcuity in a research report on Friday, November 6th. They set a "buy" rating and a $169.00 target price on the stock. Finally, Wall Street Zen upgraded Celcuity from a "strong sell" rating to a "sell" rating in a report on Saturday, November 14th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $151.79.
Read Our Latest Analysis on Celcuity
Celcuity Price Performance
The company has a quick ratio of 14.59, a current ratio of 14.62 and a debt-to-equity ratio of 6.04. The company has a fifty day simple moving average of $69.79 and a two-hundred day simple moving average of $97.15. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -11.33 and a beta of 0.16.
Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.30. On average, equities research analysts anticipate that Celcuity, Inc. will post -5.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Celcuity
A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE acquired a new position in shares of Celcuity during the 2nd quarter valued at $153,928,000. Soleus Capital Management L.P. bought a new stake in Celcuity during the third quarter valued at about $133,813,000. Assenagon Asset Management S.A. raised its holdings in Celcuity by 685.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company's stock valued at $117,579,000 after acquiring an additional 1,290,466 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Celcuity by 111.4% during the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company's stock valued at $94,848,000 after purchasing an additional 477,643 shares in the last quarter. Finally, Apis Capital Advisors LLC grew its holdings in shares of Celcuity by 5.4% in the 3rd quarter. Apis Capital Advisors LLC now owns 567,200 shares of the company's stock worth $45,104,000 after purchasing an additional 29,200 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors.
About Celcuity
(
Get Free Report)
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.